Statement Of Cash Flows [Abstract]

ABIONYX Pharma - Filing #2821124

Concept	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-01-01	2019-01-01 to 2019-12-31	As at 2019-12-31	As at 2019-01-01
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations	—	2 729 EUR	—	2 646 EUR	—	—
Income taxes paid (refund), classified as operating activities	—	0 EUR	—	0 EUR	—	—
Cash flows from (used in) operating activities	—	599,000 EUR	—	3 950 EUR	—	—
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities	—	23,000 EUR	—	0 EUR	—	—
Purchase of property, plant and equipment, classified as investing activities	—	103,000 EUR	—	0 EUR	—	—
Proceeds from sales of intangible assets, classified as investing activities	—	0 EUR	—	0 EUR	—	—
Purchase of intangible assets, classified as investing activities	—	45,000 EUR	—	0 EUR	—	—
Cash flows from (used in) investing activities	—	125,000 EUR	—	0 EUR	—	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	—	1 836 EUR	—	939,000 EUR	—	—
Proceeds from borrowings, classified as financing activities	—	0 EUR	—	250,000 EUR	—	—
Repayments of borrowings, classified as financing activities	—	200,000 EUR	—	400,000 EUR	—	—
Cash flows from (used in) financing activities	—	1 547 EUR	—	823,000 EUR	—	—
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	—	823,000 EUR	—	3 127 EUR	—	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	0 EUR	—	0 EUR	—	—
Cash and cash equivalents	9 154 EUR	—	8 331 EUR	—	8 331 EUR	11 457 EUR